真实世界中患有外周神经母细胞瘤儿童的疫苗接种现状和安全性。
Current vaccination status and safety of children with peripheral neuroblastoma in the real-world.
机构信息
Department of Pediatric Hematology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
出版信息
Front Immunol. 2024 Jan 8;14:1278258. doi: 10.3389/fimmu.2023.1278258. eCollection 2023.
BACKGROUND
peripheral neuroblastic tumors (pNT) have high incidence and mortality, and infants are prone to various infectious diseases. The purpose of this study is to understand the immunization status of children with pNT in the real-world and the incidence of adverse reactions after vaccination, and to evaluate the feasibility of vaccination and the influencing factors of vaccination.
METHODS
Children with pNT treated in the Children's Hospital Affiliated to Zhejiang University from January 1, 2011 to December 1, 2021 were included. By referring to medical records, the vaccination history of the national immunization program (NIP) vaccines and the occurrence of adverse events following immunization(AEFI), current status and safety of immunization in children with pNT in the real-world were analyzed.
RESULTS
Among 784 children with pNT, 394 were able to obtain the history of vaccination. The overall vaccination rate of NIP vaccines was 71.49% before chemotherapy and 37.67% after chemotherapy, and the recovery time of vaccination after treatment was 16.00 (6.00,24.00) months. Age, time of tumor diagnosis and disease classification were significantly correlated with vaccination. AEFI reported an incidence of 0.23‰.
CONCLUSION
The vaccination rate of children with pNT is generally low, especially the vaccination rate after chemotherapy. The vaccination safety is good, children should be encouraged to immunize.
背景
外周神经母细胞瘤（pNT）发病率和死亡率高，婴幼儿易发生各种感染性疾病。本研究旨在了解真实世界中 pNT 患儿的免疫接种状况及疫苗接种后不良反应的发生情况，评估接种的可行性及其影响因素。
方法
纳入 2011 年 1 月 1 日至 2021 年 12 月 1 日在浙江大学附属儿童医院治疗的 pNT 患儿。通过查阅病历，分析儿童 pNT 真实世界中国家免疫规划（NIP）疫苗的接种史及预防接种不良反应（AEFI）的发生情况、现状和安全性。
结果
784 例 pNT 患儿中，394 例可获得疫苗接种史。化疗前 NIP 疫苗总体接种率为 71.49%，化疗后为 37.67%，治疗后恢复接种的时间为 16.00（6.00，24.00）个月。年龄、肿瘤诊断时间和疾病分类与接种显著相关。报告 AEFI 的发生率为 0.23‰。
结论
pNT 患儿的接种率总体较低，尤其是化疗后的接种率。疫苗接种安全性良好，应鼓励儿童进行免疫接种。
Zotero 插件